RU2015144193A - Галогенпиразолы в качестве ингибиторов тромбина - Google Patents
Галогенпиразолы в качестве ингибиторов тромбина Download PDFInfo
- Publication number
- RU2015144193A RU2015144193A RU2015144193A RU2015144193A RU2015144193A RU 2015144193 A RU2015144193 A RU 2015144193A RU 2015144193 A RU2015144193 A RU 2015144193A RU 2015144193 A RU2015144193 A RU 2015144193A RU 2015144193 A RU2015144193 A RU 2015144193A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- unsubstituted
- fluoro
- chlorothiophen
- methyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000003118 aryl group Chemical group 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- -1 5 - [(5-chlorothiophen-2-yl) methyl] amino-4-fluoro-3- (oxan-4-yl) -1H-pyrazol-1-yl Chemical group 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000001544 thienyl group Chemical group 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 208000007536 Thrombosis Diseases 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000003566 oxetanyl group Chemical group 0.000 claims 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010014513 Embolism arterial Diseases 0.000 claims 2
- 206010014522 Embolism venous Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 230000001269 cardiogenic effect Effects 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000004043 venous thromboembolism Diseases 0.000 claims 2
- VVVRDPJUHPXOME-UHFFFAOYSA-N 1-[4-[5-[(5-chlorothiophen-2-yl)methylamino]-1-(2,3-dihydro-1,4-benzodioxine-5-carbonyl)-4-fluoropyrazol-3-yl]phenyl]pyrrolidin-2-one Chemical compound C=1C=CC=2OCCOC=2C=1C(=O)N1N=C(C=2C=CC(=CC=2)N2C(CCC2)=O)C(F)=C1NCC1=CC=C(Cl)S1 VVVRDPJUHPXOME-UHFFFAOYSA-N 0.000 claims 1
- GKYCDIHRVHGHIP-UHFFFAOYSA-N 1-[4-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-1-(2-methoxybenzoyl)pyrazol-3-yl]phenyl]pyrrolidin-2-one Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2C=CC(=CC=2)N2C(CCC2)=O)=N1 GKYCDIHRVHGHIP-UHFFFAOYSA-N 0.000 claims 1
- HHGALJPSBFASOJ-UHFFFAOYSA-N 1-[5-(benzylamino)-4-fluoro-3-phenylpyrazol-1-yl]-2,2-dimethylpropan-1-one Chemical compound CC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=CC=C1 HHGALJPSBFASOJ-UHFFFAOYSA-N 0.000 claims 1
- JYCHAIMVFMTDKR-UHFFFAOYSA-N 1-[5-(benzylamino)-4-fluoro-3-pyridin-2-ylpyrazol-1-yl]-2,2-dimethylpropan-1-one Chemical compound CC(C)(C)C(=O)N1N=C(C=2N=CC=CC=2)C(F)=C1NCC1=CC=CC=C1 JYCHAIMVFMTDKR-UHFFFAOYSA-N 0.000 claims 1
- HRLKXNFBOABUKO-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-3-[1-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperidin-4-yl]-4-fluoropyrazol-1-yl]-3-hydroxy-2,2-dimethylpropan-1-one Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(CC1)CCC1C(C=1F)=NN(C(=O)C(C)(C)CO)C=1NCC1=CC=C(Cl)S1 HRLKXNFBOABUKO-UHFFFAOYSA-N 0.000 claims 1
- LUDFIQPKZDFJEM-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)pyrazol-1-yl]-2,2-dimethylpropan-1-one Chemical compound CC(C)(C)C(=O)N1N=C(C=2C=C3CCCC(O)C3=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 LUDFIQPKZDFJEM-UHFFFAOYSA-N 0.000 claims 1
- KEJQPLBDPVKEMM-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-3-hydroxy-2,2-dimethylpropan-1-one Chemical compound FC1=C(NCC=2SC(Cl)=CC=2)N(C(=O)C(C)(CO)C)N=C1C1CCOCC1 KEJQPLBDPVKEMM-UHFFFAOYSA-N 0.000 claims 1
- HMNBVVOSLOHPOL-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-3-methoxy-2,2-dimethylpropan-1-one Chemical compound FC1=C(NCC=2SC(Cl)=CC=2)N(C(=O)C(C)(C)COC)N=C1C1CCOCC1 HMNBVVOSLOHPOL-UHFFFAOYSA-N 0.000 claims 1
- YKXZEZIMLOLTLH-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-2,2-dimethylpropan-1-one Chemical compound CC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 YKXZEZIMLOLTLH-UHFFFAOYSA-N 0.000 claims 1
- YNSLDHRLLMPSNB-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-2-hydroxy-2-methylpropan-1-one Chemical compound CC(C)(O)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 YNSLDHRLLMPSNB-UHFFFAOYSA-N 0.000 claims 1
- JPIBTSRVHVXZBN-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-2-methoxy-2-methylpropan-1-one Chemical compound COC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 JPIBTSRVHVXZBN-UHFFFAOYSA-N 0.000 claims 1
- QILSBTDHXMFDCU-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-3-(2-methoxyethoxy)-2,2-dimethylpropan-1-one Chemical compound COCCOCC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 QILSBTDHXMFDCU-UHFFFAOYSA-N 0.000 claims 1
- YMUNSTMHICDGNC-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-3-hydroxy-2,2-dimethylpropan-1-one Chemical compound OCC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 YMUNSTMHICDGNC-UHFFFAOYSA-N 0.000 claims 1
- SWTDJZNFPFJRQP-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-3-methoxy-2,2-dimethylpropan-1-one Chemical compound COCC(C)(C)C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 SWTDJZNFPFJRQP-UHFFFAOYSA-N 0.000 claims 1
- OUSJHIBXTVEEFG-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-2-methoxy-2-methylpropan-1-one Chemical compound FC1=C(NCC=2SC(Cl)=CC=2)N(C(=O)C(C)(C)OC)N=C1C1CCNCC1 OUSJHIBXTVEEFG-UHFFFAOYSA-N 0.000 claims 1
- DJVJRNGBPQDBJO-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-3-hydroxy-2,2-dimethylpropan-1-one Chemical compound FC1=C(NCC=2SC(Cl)=CC=2)N(C(=O)C(C)(CO)C)N=C1C1CCNCC1 DJVJRNGBPQDBJO-UHFFFAOYSA-N 0.000 claims 1
- UMADNIUGPMKADU-UHFFFAOYSA-N 1-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-3-methoxy-2,2-dimethylpropan-1-one Chemical compound FC1=C(NCC=2SC(Cl)=CC=2)N(C(=O)C(C)(C)COC)N=C1C1CCNCC1 UMADNIUGPMKADU-UHFFFAOYSA-N 0.000 claims 1
- DRULVWVSZKGIIH-UHFFFAOYSA-N 6-[5-[(5-chlorothiophen-2-yl)methylamino]-1-(2,2-dimethylpropanoyl)-4-fluoropyrazol-3-yl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound CC(C)(C)C(=O)N1N=C(C=2C=C3CCCC(=O)C3=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 DRULVWVSZKGIIH-UHFFFAOYSA-N 0.000 claims 1
- CFYNRMPDOAJILH-UHFFFAOYSA-N 6-[5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-1-(2-methoxybenzoyl)pyrazol-3-yl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2C=C3CCCC(=O)C3=CC=2)=N1 CFYNRMPDOAJILH-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- JTVDTAQXPNXTGX-UHFFFAOYSA-N [3-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-5-(oxan-4-yl)pyrazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-5-yl)methanone Chemical compound N=1N(C(=O)C=2C=3OCCOC=3C=CC=2)C(C2CCOCC2)=C(F)C=1NCC1=CC=C(Cl)S1 JTVDTAQXPNXTGX-UHFFFAOYSA-N 0.000 claims 1
- JJYAQOXBURBKGN-UHFFFAOYSA-N [3-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-5-(oxan-4-yl)pyrazol-1-yl]-(2,4-dimethoxyphenyl)methanone Chemical compound COC1=CC(OC)=CC=C1C(=O)N1C(C2CCOCC2)=C(F)C(NCC=2SC(Cl)=CC=2)=N1 JJYAQOXBURBKGN-UHFFFAOYSA-N 0.000 claims 1
- AQWRTUWBEIODPC-UHFFFAOYSA-N [3-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-5-(oxan-4-yl)pyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(C2CCOCC2)=C(F)C(NCC=2SC(Cl)=CC=2)=N1 AQWRTUWBEIODPC-UHFFFAOYSA-N 0.000 claims 1
- NWSTZAZCBVHZCY-UHFFFAOYSA-N [3-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-5-(oxan-4-yl)pyrazol-1-yl]-phenylmethanone Chemical compound N=1N(C(=O)C=2C=CC=CC=2)C(C2CCOCC2)=C(F)C=1NCC1=CC=C(Cl)S1 NWSTZAZCBVHZCY-UHFFFAOYSA-N 0.000 claims 1
- WVWCTFWUTCJOFM-UHFFFAOYSA-N [3-[(5-chlorothiophen-2-yl)methylamino]-5-[1-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperidin-4-yl]-4-fluoropyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(C2CCN(CC2)S(=O)(=O)C=2C3=CC=CC(=C3C=CC=2)N(C)C)=C(F)C(NCC=2SC(Cl)=CC=2)=N1 WVWCTFWUTCJOFM-UHFFFAOYSA-N 0.000 claims 1
- RFJMJKBGUAGIFO-UHFFFAOYSA-N [4-[3-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-1h-pyrazol-5-yl]piperidin-1-yl]-(1-hydroxycyclopropyl)methanone Chemical compound C1CC(C2=C(C(NCC=3SC(Cl)=CC=3)=NN2)F)CCN1C(=O)C1(O)CC1 RFJMJKBGUAGIFO-UHFFFAOYSA-N 0.000 claims 1
- VQFCADVXAYMBNM-UHFFFAOYSA-N [5-(benzylamino)-4-fluoro-3-phenylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=C(F)C(C=2C=CC=CC=2)=N1 VQFCADVXAYMBNM-UHFFFAOYSA-N 0.000 claims 1
- ZSASFIQLWSZLFG-UHFFFAOYSA-N [5-(benzylamino)-4-fluoro-3-pyridin-2-ylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=C(F)C(C=2N=CC=CC=2)=N1 ZSASFIQLWSZLFG-UHFFFAOYSA-N 0.000 claims 1
- RERBYEJMKXCEAV-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-3-[1-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperidin-4-yl]-4-fluoropyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCN(CC2)S(=O)(=O)C=2C3=CC=CC(=C3C=CC=2)N(C)C)=N1 RERBYEJMKXCEAV-UHFFFAOYSA-N 0.000 claims 1
- WNLXJTRUJQCYRU-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-5-yl)methanone Chemical compound C=1C=CC=2OCCOC=2C=1C(=O)N1N=C(C2CCOCC2)C(F)=C1NCC1=CC=C(Cl)S1 WNLXJTRUJQCYRU-UHFFFAOYSA-N 0.000 claims 1
- YYNNIVLDVFDWTL-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(2,4-dimethoxyphenyl)methanone Chemical compound COC1=CC(OC)=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCOCC2)=N1 YYNNIVLDVFDWTL-UHFFFAOYSA-N 0.000 claims 1
- LMEURFSIHPOQNR-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCOCC2)=N1 LMEURFSIHPOQNR-UHFFFAOYSA-N 0.000 claims 1
- ZDXDVCZQVQEJMG-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(4-methyloxan-4-yl)methanone Chemical compound N1=C(C2CCOCC2)C(F)=C(NCC=2SC(Cl)=CC=2)N1C(=O)C1(C)CCOCC1 ZDXDVCZQVQEJMG-UHFFFAOYSA-N 0.000 claims 1
- PLCIVTUFAXTGQS-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(4-morpholin-4-ylphenyl)methanone Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(=O)N1N=C(C2CCOCC2)C(F)=C1NCC1=CC=C(Cl)S1 PLCIVTUFAXTGQS-UHFFFAOYSA-N 0.000 claims 1
- YDQDBKJMDXVZLY-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-(furan-3-yl)methanone Chemical compound C1=COC=C1C(=O)N1N=C(C2CCOCC2)C(F)=C1NCC1=CC=C(Cl)S1 YDQDBKJMDXVZLY-UHFFFAOYSA-N 0.000 claims 1
- YIEMZHOIAYJNHX-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-[1-(hydroxymethyl)cyclopropyl]methanone Chemical compound N1=C(C2CCOCC2)C(F)=C(NCC=2SC(Cl)=CC=2)N1C(=O)C1(CO)CC1 YIEMZHOIAYJNHX-UHFFFAOYSA-N 0.000 claims 1
- PWWFYQHPSAIRTE-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-[4-(2-methoxyethoxy)phenyl]methanone Chemical compound C1=CC(OCCOC)=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCOCC2)=N1 PWWFYQHPSAIRTE-UHFFFAOYSA-N 0.000 claims 1
- GIGLTYCAUZBJQL-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)N1N=C(C2CCOCC2)C(F)=C1NCC1=CC=C(Cl)S1 GIGLTYCAUZBJQL-UHFFFAOYSA-N 0.000 claims 1
- ABLJXAXKFVPREL-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-(oxan-4-yl)pyrazol-1-yl]-thiophen-3-ylmethanone Chemical compound C1=CSC=C1C(=O)N1N=C(C2CCOCC2)C(F)=C1NCC1=CC=C(Cl)S1 ABLJXAXKFVPREL-UHFFFAOYSA-N 0.000 claims 1
- RSNNCZRERIBJKL-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]pyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2C=CC(=CC=2)C(O)C(F)(F)F)=N1 RSNNCZRERIBJKL-UHFFFAOYSA-N 0.000 claims 1
- LMRZEDUBKCAKCP-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-5-yl)methanone Chemical compound C=1C=CC=2OCCOC=2C=1C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 LMRZEDUBKCAKCP-UHFFFAOYSA-N 0.000 claims 1
- YNDMMARFYKNMPF-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(2,4-dimethoxyphenyl)methanone Chemical compound COC1=CC(OC)=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2C=CC=CC=2)=N1 YNDMMARFYKNMPF-UHFFFAOYSA-N 0.000 claims 1
- AZPGIWCVHYJJSN-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2C=CC=CC=2)=N1 AZPGIWCVHYJJSN-UHFFFAOYSA-N 0.000 claims 1
- XFJAVMOQYYSIFW-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(3-methyloxetan-3-yl)methanone Chemical compound N1=C(C=2C=CC=CC=2)C(F)=C(NCC=2SC(Cl)=CC=2)N1C(=O)C1(C)COC1 XFJAVMOQYYSIFW-UHFFFAOYSA-N 0.000 claims 1
- VYZHLHQLGSVAFG-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(4-methyloxan-4-yl)methanone Chemical compound N1=C(C=2C=CC=CC=2)C(F)=C(NCC=2SC(Cl)=CC=2)N1C(=O)C1(C)CCOCC1 VYZHLHQLGSVAFG-UHFFFAOYSA-N 0.000 claims 1
- BHUNAZGKKNUSFE-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-(furan-3-yl)methanone Chemical compound C1=COC=C1C(=O)N1N=C(C=2C=CC=CC=2)C(F)=C1NCC1=CC=C(Cl)S1 BHUNAZGKKNUSFE-UHFFFAOYSA-N 0.000 claims 1
- LKRDVTZSHQESMB-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-phenylpyrazol-1-yl]-[1-(hydroxymethyl)cyclopropyl]methanone Chemical compound N1=C(C=2C=CC=CC=2)C(F)=C(NCC=2SC(Cl)=CC=2)N1C(=O)C1(CO)CC1 LKRDVTZSHQESMB-UHFFFAOYSA-N 0.000 claims 1
- QTJPWWUOGPZHSV-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-(2,3-dihydro-1,4-benzodioxin-5-yl)methanone Chemical compound C=1C=CC=2OCCOC=2C=1C(=O)N1N=C(C2CCNCC2)C(F)=C1NCC1=CC=C(Cl)S1 QTJPWWUOGPZHSV-UHFFFAOYSA-N 0.000 claims 1
- DHRNXXUANUPUQS-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-(2,4-dimethoxyphenyl)methanone Chemical compound COC1=CC(OC)=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCNCC2)=N1 DHRNXXUANUPUQS-UHFFFAOYSA-N 0.000 claims 1
- NMRQZCFRTDOLDV-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C2CCNCC2)=N1 NMRQZCFRTDOLDV-UHFFFAOYSA-N 0.000 claims 1
- TUPUIJGMMTYCQZ-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-piperidin-4-ylpyrazol-1-yl]-(furan-3-yl)methanone Chemical compound C1=COC=C1C(=O)N1N=C(C2CCNCC2)C(F)=C1NCC1=CC=C(Cl)S1 TUPUIJGMMTYCQZ-UHFFFAOYSA-N 0.000 claims 1
- MVTNAJPKGNDKOB-UHFFFAOYSA-N [5-[(5-chlorothiophen-2-yl)methylamino]-4-fluoro-3-pyridin-2-ylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2SC(Cl)=CC=2)=C(F)C(C=2N=CC=CC=2)=N1 MVTNAJPKGNDKOB-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789358P | 2013-03-15 | 2013-03-15 | |
| US61/789,358 | 2013-03-15 | ||
| US201361899588P | 2013-11-04 | 2013-11-04 | |
| US61/899,588 | 2013-11-04 | ||
| PCT/US2014/000058 WO2014149139A2 (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144193A true RU2015144193A (ru) | 2017-04-24 |
Family
ID=51538179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144193A RU2015144193A (ru) | 2013-03-15 | 2014-03-17 | Галогенпиразолы в качестве ингибиторов тромбина |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479749B2 (ja) | 2013-03-15 | 2019-03-06 | ヴァーセオン コーポレイション | トロンビン阻害剤としてのハロゲノピラゾール |
| BR112015022340A2 (pt) | 2013-03-15 | 2017-07-18 | Verseon Corp | método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica |
| LT3261639T (lt) * | 2015-02-27 | 2022-11-25 | Verseon International Corporation | Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai |
| KR20220004083A (ko) | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태 |
| CN112062692A (zh) * | 2019-06-11 | 2020-12-11 | 太仓市茜泾化工有限公司 | 一种乙氧甲叉氰基乙酸乙酯的制备方法 |
| CN112986065B (zh) * | 2021-02-08 | 2021-08-31 | 杭州同创医学检验实验室有限公司 | 一种用于血细胞分析仪的全血质控品及其制备方法 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1323438A (en) * | 1919-12-02 | of niagara falls | ||
| US188918A (en) * | 1877-03-27 | Improvement in towel-racks | ||
| BE627393A (cg-RX-API-DMAC7.html) | 1962-01-23 | |||
| BE793955A (fr) | 1972-01-15 | 1973-07-12 | Merck Patent Gmbh | Arylpiperazines et leur procede de preparation |
| DE2409753A1 (de) | 1974-03-01 | 1975-09-11 | Basf Ag | Substituierte pyrazole |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| IL82542A0 (en) | 1986-05-23 | 1987-11-30 | Smithkline Beckman Corp | Triazole derivatives,their preparation and pharmaceutical compositions containing them |
| JPH089541B2 (ja) | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | ピラゾール類を主成分とする脳浮腫抑制剤 |
| JP2784925B2 (ja) * | 1988-09-07 | 1998-08-13 | 日本農薬株式会社 | ３又は５−フェニルピラゾール類又はその塩及び除草剤 |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JP3810097B2 (ja) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| KR100263817B1 (ko) | 1993-11-30 | 2000-08-16 | 윌리암스 로저 에이 | 염증치료용 치환 피라졸일벤젠술폰아미드 |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| ATE262902T1 (de) | 1994-11-10 | 2004-04-15 | Millennium Pharm Inc | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
| US5733955A (en) | 1995-02-10 | 1998-03-31 | The Goodyear Tire & Rubber Company | Asphalt cement modification |
| JP3663522B2 (ja) * | 1995-08-12 | 2005-06-22 | 日本農薬株式会社 | 植物生育調節用組成物及びその使用方法 |
| US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| US5739083A (en) | 1995-10-13 | 1998-04-14 | Otsuka Kagaku Kabushiki Kaisha | Pyrazole derivatives and insecticidal compositions containing the derivative as active component |
| CA2262686A1 (en) * | 1996-08-12 | 1998-02-19 | Mark E. Fraley | Thrombin inhibitors |
| US5792761A (en) * | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
| DE19632773A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
| GB9622370D0 (en) | 1996-10-28 | 1997-01-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| IL130286A0 (en) | 1996-12-23 | 2000-06-01 | Du Pont Pharm Co | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| CN1250446A (zh) | 1997-03-21 | 2000-04-12 | 诺瓦提斯公司 | 作为除草剂的吡唑衍生物 |
| AU5510799A (en) | 1998-08-11 | 2000-03-06 | Nihon Bayer Agrochem K.K. | Nematicidal pyrazoles |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| WO2000071536A1 (en) * | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| JP2003507329A (ja) | 1999-08-12 | 2003-02-25 | フアルマシア・イタリア・エツセ・ピー・アー | ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用 |
| NZ517828A (en) | 1999-09-17 | 2003-10-31 | Millennium Pharm Inc | Inhibitors having activity against mammalian factor Xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6673820B2 (en) | 1999-12-02 | 2004-01-06 | Novartis Animal Health Us, Inc. | Aminoheterocyclylamides as pesticides and antiparasitic agents |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| US6884804B2 (en) | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| SI21097A (sl) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Inhibitorji trombina |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP2003313103A (ja) * | 2002-02-20 | 2003-11-06 | Sankyo Agro Kk | ４−アシルアミノピラゾール誘導体を有効成分として含有する農薬 |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| NZ538339A (en) | 2002-08-09 | 2007-01-26 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| WO2004035564A1 (en) | 2002-10-17 | 2004-04-29 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| MXPA05006200A (es) | 2002-12-23 | 2005-08-19 | Aventis Pharma Gmbh | Derivados de pirazol como inhibidores del factor xa. |
| US20060229335A1 (en) * | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| JP2004231528A (ja) * | 2003-01-28 | 2004-08-19 | Sankyo Agro Kk | アミド誘導体 |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| PL1618092T3 (pl) * | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
| TW200509910A (en) * | 2003-05-02 | 2005-03-16 | Elan Pharm Inc | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
| EP1479679A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| JP2007513058A (ja) | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア，インコーポレイテッド | サイトカイン阻害剤 |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| JP5319113B2 (ja) * | 2004-03-26 | 2013-10-16 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| JP2008526887A (ja) | 2005-01-10 | 2008-07-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なヘテロピロール類似体 |
| EP1867331A4 (en) | 2005-04-06 | 2009-04-08 | Takeda Pharmaceutical | TRIAZOLE DERIVATIVE AND USE THEREOF |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| CN100427481C (zh) | 2005-05-26 | 2008-10-22 | 沈阳化工研究院 | 一种芳基醚类化合物及其制备与应用 |
| WO2007067836A2 (en) | 2005-12-05 | 2007-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| BRPI0715492A2 (pt) | 2006-07-17 | 2013-03-19 | Boehringer Ingelheim Int | uso de inibidores diretos de trombina |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
| WO2008062739A1 (en) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100144793A1 (en) * | 2006-11-24 | 2010-06-10 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| JP2010513519A (ja) | 2006-12-22 | 2010-04-30 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼインヒビター活性を有するある種のピラゾリン誘導体 |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| BRPI0815112A2 (pt) * | 2007-08-06 | 2015-08-25 | Dainippon Sumitomo Pharma Co | Derivado de aminopirazol amida |
| US8334301B2 (en) | 2007-09-28 | 2012-12-18 | Takeda Pharmaceutical Company Limited | 5-Membered heterocyclic compound |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| WO2009100438A2 (en) | 2008-02-07 | 2009-08-13 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh-1 expression |
| EP2300004A4 (en) | 2008-05-15 | 2012-05-30 | Univ Duke | COMPOSITIONS AND METHODS RELATED TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING CONNECTIONS AND OBJECTS THEREFOR |
| EP2300435A2 (en) | 2008-05-19 | 2011-03-30 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| CA2767331A1 (en) | 2008-07-10 | 2010-01-14 | Angion Biomedica Corp. | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| WO2010017902A1 (de) * | 2008-08-14 | 2010-02-18 | Bayer Cropscience Aktiengesellschaft | Insektizide 4-phenyl-1h-pyrazole |
| EP2331096A1 (en) | 2008-08-19 | 2011-06-15 | Boehringer Ingelheim International GmbH | Dabigatran in tumour therapy |
| NZ591108A (en) | 2008-08-19 | 2012-11-30 | Boehringer Ingelheim Int | Dabigatran for percutaneous interventional cardiac catheterisation |
| EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| AR076753A1 (es) | 2009-05-07 | 2011-07-06 | Gruenenthal Chemie | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. |
| RU2639876C2 (ru) | 2010-03-30 | 2017-12-25 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| CN101851207B (zh) | 2010-06-11 | 2012-01-25 | 扬州康伊尔医药科技有限公司 | 抗病毒化合物中间体1-酰基-吡唑-3-羧酸及其制备方法 |
| EP2604602A4 (en) * | 2010-08-11 | 2013-12-18 | Taisho Pharmaceutical Co Ltd | HETEROARYL PYRAZOLE DERIVATIVE |
| AP3821A (en) * | 2010-11-03 | 2016-09-30 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| CN103917235A (zh) | 2011-05-17 | 2014-07-09 | 普莱希科公司 | 激酶调节及其适应症 |
| WO2013039985A2 (en) | 2011-09-12 | 2013-03-21 | The Johns Hopkins University | Serine protease inhibitors |
| WO2013049591A2 (en) | 2011-09-29 | 2013-04-04 | Verseon Corporation | Dual inhibitor compounds and methods of use thereof |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| BR112015022340A2 (pt) | 2013-03-15 | 2017-07-18 | Verseon Corp | método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica |
| JP6479749B2 (ja) | 2013-03-15 | 2019-03-06 | ヴァーセオン コーポレイション | トロンビン阻害剤としてのハロゲノピラゾール |
-
2014
- 2014-03-17 JP JP2016500154A patent/JP6479749B2/ja active Active
- 2014-03-17 EP EP14769269.3A patent/EP2970141B1/en active Active
- 2014-03-17 CN CN201480027721.XA patent/CN105209440B/zh active Active
- 2014-03-17 CA CA2902431A patent/CA2902431A1/en not_active Abandoned
- 2014-03-17 KR KR1020157027980A patent/KR20150130405A/ko not_active Ceased
- 2014-03-17 WO PCT/US2014/000058 patent/WO2014149139A2/en not_active Ceased
- 2014-03-17 ES ES14769269T patent/ES2791749T3/es active Active
- 2014-03-17 US US14/776,641 patent/US9951025B2/en active Active
- 2014-03-17 AU AU2014238478A patent/AU2014238478B2/en active Active
- 2014-03-17 BR BR112015023214A patent/BR112015023214A8/pt not_active IP Right Cessation
- 2014-03-17 MX MX2015011567A patent/MX373646B/es active IP Right Grant
- 2014-03-17 RU RU2015144193A patent/RU2015144193A/ru not_active Application Discontinuation
- 2014-03-17 SG SG10201707486XA patent/SG10201707486XA/en unknown
- 2014-03-17 CN CN201910623548.4A patent/CN110423221A/zh active Pending
- 2014-03-17 HK HK16102083.6A patent/HK1214252A1/zh unknown
- 2014-03-17 SG SG11201506757TA patent/SG11201506757TA/en unknown
- 2014-03-18 WO PCT/US2014/030937 patent/WO2014146059A1/en not_active Ceased
-
2015
- 2015-08-23 IL IL24076315A patent/IL240763B/en not_active IP Right Cessation
- 2015-09-02 ZA ZA2015/06440A patent/ZA201506440B/en unknown
-
2018
- 2018-02-27 US US15/907,045 patent/US20180186751A1/en not_active Abandoned
- 2018-10-19 AU AU2018250514A patent/AU2018250514A1/en not_active Abandoned
-
2019
- 2019-02-06 JP JP2019019308A patent/JP2019081782A/ja active Pending
-
2020
- 2020-06-16 JP JP2020103499A patent/JP2020158522A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160046585A1 (en) | 2016-02-18 |
| IL240763B (en) | 2019-11-28 |
| EP2970141A4 (en) | 2016-08-31 |
| AU2018250514A1 (en) | 2018-11-15 |
| ES2791749T3 (es) | 2020-11-05 |
| BR112015023214A8 (pt) | 2019-12-24 |
| MX373646B (es) | 2020-04-02 |
| JP2020158522A (ja) | 2020-10-01 |
| KR20150130405A (ko) | 2015-11-23 |
| SG10201707486XA (en) | 2017-10-30 |
| JP2019081782A (ja) | 2019-05-30 |
| JP6479749B2 (ja) | 2019-03-06 |
| CN110423221A (zh) | 2019-11-08 |
| WO2014146059A1 (en) | 2014-09-18 |
| MX2015011567A (es) | 2016-04-25 |
| IL240763A0 (en) | 2015-10-29 |
| HK1214252A1 (zh) | 2016-07-22 |
| ZA201506440B (en) | 2019-06-26 |
| CN105209440A (zh) | 2015-12-30 |
| EP2970141A2 (en) | 2016-01-20 |
| WO2014149139A3 (en) | 2014-11-27 |
| SG11201506757TA (en) | 2015-09-29 |
| AU2014238478A1 (en) | 2015-09-10 |
| BR112015023214A2 (pt) | 2017-07-18 |
| CN105209440B (zh) | 2019-07-23 |
| EP2970141B1 (en) | 2020-02-26 |
| JP2016512243A (ja) | 2016-04-25 |
| AU2014238478B2 (en) | 2018-07-19 |
| US20180186751A1 (en) | 2018-07-05 |
| WO2014149139A2 (en) | 2014-09-25 |
| US9951025B2 (en) | 2018-04-24 |
| CA2902431A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015144151A (ru) | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз | |
| RU2015144193A (ru) | Галогенпиразолы в качестве ингибиторов тромбина | |
| RU2017144535A (ru) | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина | |
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| RU2482111C2 (ru) | Соединения, обладающие противораковой активностью | |
| JP2010510319A5 (cg-RX-API-DMAC7.html) | ||
| JP2016519096A5 (cg-RX-API-DMAC7.html) | ||
| RU2019119899A (ru) | Новое дизамещенное 1,2,4-триазиновое соединение | |
| JP2015520752A5 (cg-RX-API-DMAC7.html) | ||
| RU2018141881A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| JP2016517878A5 (cg-RX-API-DMAC7.html) | ||
| RU2010123874A (ru) | Пиридазиноновые производные в качестве ингибиторов parp | |
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| RU2016114128A (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-а]ПИРИМИДИНА КАК ИНГИБИТОРЫ КИНАЗЫ TRK | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2021129721A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| JP2017537948A5 (cg-RX-API-DMAC7.html) | ||
| RU2015150946A (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| JP2008513514A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500360A5 (cg-RX-API-DMAC7.html) | ||
| JP2006500348A5 (cg-RX-API-DMAC7.html) | ||
| RU2015154987A (ru) | Гетероциклические производные | |
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2009117475A (ru) | Соединения, модулирующие активность c-fms и/или c-kit, и их применения | |
| JP2007529486A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20210129 |